Insmed to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022

Rhea-AI Summary

Insmed Incorporated (Nasdaq:INSM) will release its Q2 2022 financial results on August 4, 2022. The management will conduct a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update. Interested parties can join the call by dialling (888) 210-2654 for U.S. callers and (646) 960-0278 internationally. A replay will be available until September 3, 2022. Insmed focuses on developing therapies for serious and rare diseases and has a first-in-disease therapy approved in multiple regions.

Positive

• Insmed's first commercial product is approved in the U.S., Europe, and Japan for a chronic lung disease.
• Robust pipeline of investigational therapies targeting serious unmet needs.

Negative

• None.

BRIDGEWATER, N.J., July 21, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2022 financial results on Thursday, August 4, 2022.

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, August 4, 2022 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) or (646) 960-0278 (international) and referencing access code 7862189. The call will also be webcast live on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately 2 hours after its completion through September 3, 2022, by dialing (800) 770-2030 (U.S.) or (647) 362-9199 (international) and referencing access code 7862189. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-second-quarter-2022-financial-results-conference-call-on-thursday-august-4-2022-301590449.html

SOURCE Insmed Incorporated

FAQ

When will Insmed release its Q2 2022 financial results?

Insmed will release its Q2 2022 financial results on August 4, 2022.

What time is the Insmed conference call for Q2 2022 results?

The conference call will take place at 8:30 a.m. ET on August 4, 2022.

How can I participate in Insmed's Q2 2022 conference call?

Participants can dial (888) 210-2654 for U.S. calls or (646) 960-0278 internationally.

Where can I find more information about Insmed's conference call?

More information is available on Insmed's official website under the Investor Relations section.

What is Insmed's focus as a biopharmaceutical company?

Insmed focuses on transforming the lives of patients with serious and rare diseases.